Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset

Table 5

(a) Age at the diagnosis of PTC and risk of SPM (95% CI)

Age

30–34

35–39

40–44

45–49

50–54

55–59

60–64

65–69

O/E

95 CI%

O/E

95 CI%

O/E

95 CI%

O/E

95 CI%

O/E

95 CI%

O/E

95 CI%

O/E

95 CI%

O/E

95 CI%

All sites

1.43#

1.19–1.71

1.30#

1.13–1.49

1.19#

1.05–1.34

1.18#

1.06–1.31

1.21#

1.1–1.33

1.13#

1.02–1.24

1.17#

1.06–1.29

1.06

NS

All solid tumors

1.37#

1.12–1.66

1.22#

1.05–1.42

1.16#

1.02–1.31

1.21#

1.09–1.35

1.18#

1.06–1.31

1.11#

1.0–1.23

1.15#

1.04–1.28

1.05

NS

#: < 0.05.

(b) Age at the diagnosis of PTC and risk of SPM

	05–09 years	10–14 years	15–19 years	20–24 years	25–29 years	30–34 years	35–39 years	40–44 years	45–49 years	50–54 years	55–59 years	60–64 years	65–69 years	70–74 years	75–79 years	80–84 years	85+ years
	O/E	O/E	O/E	O/E	O/E	O/E	O/E	O/E	O/E	O/E	O/E	O/E	O/E	O/E	O/E	O/E	O/E
All sites	8.65	0	2.04	1.04	1.27	1.43#	1.30#	1.19#	1.18#	1.21#	1.13#	1.17#	1.06	1.13#	1.15	0.99	1.03
All solid tumors	12.49	0	2.13	0.9	1.25	1.37#	1.22#	1.16#	1.21#	1.18#	1.11#	1.15#	1.05	1.12	1.17#	0.99	1.04
Oral cavity and pharynx	483.18#	0	30.85#	0	2.84	2.66	1.29	1.41	1.21	1.29	1.04	1.06	0.79	1.12	1	2.82	0
Salivary gland	965.63#	0	76.55#	0	11.72#	3.63	2.34	5.27#	4.38	5.10#	3.74	4.01	2.57	1.64	2.19	4.38	0
Rectum and rectosigmoid junction	0	0	0	0	3.41	1.46	0.72	1.4	0.61	0.77	0.55	0.12#	0.69	0.75	0.83	0.83	0
Bones and joints	0	0	0	10.45	6.23	4.37	3.08	2.67	5.25	0	9.24#	7.5	3.78	0	7.15	0	0
Skin excluding basal and squamous	0	0	0	0.49	0.93	2.12#	1.11	0.91	1.3	1.74#	2.04#	1.07	1.48	1.88#	0.59	1.3	2.59
Melanoma of the skin	0	0	0	0.52	0.98	2.08#	0.88	0.88	1.38	1.65#	2.06#	1.09	1.41	1.69	0.53	1.19	3.23
Breast	0	0	3.14	0.00#	1.27	1.52#	1.21	1.21	1.11	1.16	1.17	0.97	1.19	1.3	1.24	0.93	0.84
Female genital system	0	0	2	1.31	1.37	0.71	1.02	1.13	1.07	0.98	1.1	1.08	0.8	0.86	1.28	0.93	1.04
Male genital system	0	0	0	3.24	1.3	2.5	2.35#	1.41	1.56#	1.48#	1.13	1.26	0.79	1.35	0.99	1.03	0.71
Prostate	0	0	0	0	0	1.03	2.52#	1.39	1.51#	1.47#	1.12	1.27	0.79	1.36	1.01	1.04	0.72
Testis	0	0	0	3.5	0	4.98#	1.53	1.94	2.8	0	0	0	0	0	0	0	0
Urinary bladder	0	0	0	10.22	0	0	1	0.51	0.74	1.19	1.52	1.45	1.13	1.29	1.83#	1.02	2.82
Kidney	0	0	0	0	1.1	2.03	2.83#	2.50#	2.61#	1.73#	2.07#	2.65#	3.03#	1.39	1.09	0	0
Renal pelvis	0	0	0	0	0	0	0	5.73	0	0	0	2.68	0	1.29	6.83#	7.38	0
All lymphatic and hematopoietic diseases	0	0	1.73	2.27	1.38	2.27#	1.98#	1.61#	0.82	1.31	1.17	1.50#	1.24	1.21	0.98	1.1	1.55
Lymphoma	0	0	2.44	2.42	1.22	2	1.99#	1.3	0.85	1.05	1.13	1.22	0.95	1.31	1.03	1.24	1.29
Leukemia	0	0	0	2.13	2.05	3.61#	2.43	2.81#	1.03	1.76	1.33	1.90#	1.38	0.78	1.04	0.69	1.68
Acute lymphocytic leukemia	0	0	0	0	0	4.36	6.55	8.52#	2.59	2.53	2.93	7.25	7.85	0	0	0	0
Chronic lymphocytic leukemia	0	0	0	0	0	0	0	3.50#	0.87	1.86	0.8	1.56	1.44	0.3	0.81	0.83	0
Acute nonlymphocytic leukemia (ANLL)	0	0	0	4.5	4.65	5.97#	1.87	0.67	0	1.67	2.23	1.77	1.53	1.5	1.49	1.02	5.08
Myeloid and monocytic leukemia	0	0	0	3.16	3.14	4.97#	3.14#	1.85	1.1	1.82	1.92	1.86	1.17	1.15	1.15	0.8	4.02
Acute myeloid leukemia	0	0	0	4.97	2.58	6.63#	1.04	0.74	0	1.84	2.46	1.96	1.71	1.72	1.74	1.24	6.38
Acute monocytic leukemia	0	0	0	0	39.3	0	13.61	0	0	0	0	0	0	0	0	0	0
Chronic myeloid leukemia	0	0	0	0	0	2.97	5.75#	4.43	3.73	2.15	1.01	2.01	0	0	0	0	0

#: < 0.05.